CANTATA: CB-839 and Cabozanitib versus Cabozanitib and Placebo
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

CANTATA: CB-839 and Cabozanitib versus Cabozanitib and Placebo

Sponsor: Calithera Biosciences, Inc

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC).